Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum.
Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B, So AI, Aaron L, Basappa NS, Conter HJ, Danielson B, Gotto G, Hamilton RJ, Izard JP, Kapoor A, Kolinsky M, Lalani AA, Lattouf JB, Morash C, Morgan SC, Niazi T, Noonan KL, Ong M, Rendon RA, Sehdev S, Hew H, Park-Wyllie L, Chi KN. Saad F, et al. Among authors: ong m. Can Urol Assoc J. 2020 Apr;14(4):E137-E149. doi: 10.5489/cuaj.6082. Epub 2019 Nov 5. Can Urol Assoc J. 2020. PMID: 31702544 Free PMC article. Review.
Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.
Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M. Fernandes R, et al. Among authors: ong m. Support Care Cancer. 2018 Sep;26(9):3073-3081. doi: 10.1007/s00520-018-4161-x. Epub 2018 Mar 21. Support Care Cancer. 2018. PMID: 29564623
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.
Black PC, Alimohamed NS, Berman D, Blais N, Eigl B, Karakiewicz PI, Kassouf W, Kulkarni GS, Ong M, Spatz A, Sridhar SS, Stockley T, van der Kwast T, Hew H, Park-Wyllie L, North SA. Black PC, et al. Among authors: ong m. Can Urol Assoc J. 2020 Aug;14(8):E373-E382. doi: 10.5489/cuaj.6458. Can Urol Assoc J. 2020. PMID: 32209217 Free PMC article. Review.
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
Kassouf W, Aprikian A, Saad F, Fleshner N, Alimohamed N, Breau RH, Brimo F, Chin J, Chung P, Cornacchia T, Devins F, Eapen L, Eigl B, Fairey A, Guttman D, Izard JP, Jacobsen N, Jeldres C, Kulkarni G, Lalani AK, Lodde M, Lukka H, Moore R, Morash C, North S, Northam T, Ong M, Power N, Rendon R, Purves R, Shayegan B, Smith R, So A, Sridhar SS, Zlotta A, Siemens DR, Black PC. Kassouf W, et al. Among authors: ong m. Can Urol Assoc J. 2020 Mar;14(3):E115-E125. doi: 10.5489/cuaj.6378. Epub 2020 Feb 3. Can Urol Assoc J. 2020. PMID: 32453694 Free PMC article. No abstract available.
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.
Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, Sorabji D, Hew H, Park-Wyllie L, Saad F. Hotte SJ, et al. Among authors: ong m. Can Urol Assoc J. 2021 Feb;15(2):E90-E96. doi: 10.5489/cuaj.6779. Can Urol Assoc J. 2021. PMID: 32853135 Free PMC article.
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, Mates M, Robinson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D; REaCT investigators. Clemons M, et al. Among authors: ong m. Eur J Cancer. 2021 Jan;142:132-140. doi: 10.1016/j.ejca.2020.08.019. Epub 2020 Oct 3. Eur J Cancer. 2021. PMID: 33023785 Free PMC article. Clinical Trial.
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schönlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN. Annala M, et al. Among authors: ong m. Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6. Ann Oncol. 2021. PMID: 33836265 Free article. Clinical Trial.
1,272 results